Our Team

Mr. Fassberg is the Founder and Chief Executive Officer of Trout Capital. He has worked in the life sciences industry for 15 years and been an advisor to senior management of over 100 companies, both public and private. Prior to founding Trout, Jonathan was a sell-side analyst at a healthcare-focused investment bank. Before his career on Wall Street, Jonathan spent four years at DuPont Pharma in various sales and marketing positions.

Jonathan holds a Bachelor of Science degree in biology and chemistry from The University of North Carolina – Chapel Hill and a Master of Business Administration degree in finance from New York University’s Stern School of Business. He also holds Series 7, 24 and 63 securities licenses.

Close

Mr. Stern has a broad array of experience in investor relations, management consulting and finance. Since joining Trout, he has worked with numerous health sciences companies to develop and implement their investor positioning strategies, assisted companies with capital-raising strategies and advised senior management on general company strategy. His responsibilities also include daily operations of the firm.

Lee holds a Bachelor of Science degree in quantitative economics from Tufts University and is a Chartered Financial Analyst (CFA). He also holds Series 7, 24 and 63 securities licenses. He is a member of the New York Society of Security Analysts (NYSSA) and the CFA Institute. He also plays drums for a New York-based rock and roll band.

Close

Mr. Levitan joined the firm in 2007 to expand the capital-raising, M&A and strategic advisory services efforts provided through Trout Capital LLC. Mr. Levitan has 16 years of experience in healthcare investment banking and corporate development, principally focused on the biotechnology, pharmaceuticals, life sciences and life science IT sectors. He has executed a broad range of healthcare transactions totaling over $3 billion in value. He has senior-level experience with boutique investment banks and with Bear Stearns in New York. Michael began his investment banking career at Lehman Brothers in 1996. Before that, he worked at Eli Lilly and Company in medical device and pharmaceuticals business development.

He also holds Series 7 and 63 securities licenses.

Close

Ms. Labaree joined the firm with more than 10 years of experience in healthcare investor relations, public relations, corporate and marketing communications and product marketing. Christine came to Trout from Biocompatibles International PLC, a biopolymer drug delivery company where she was Corporate Communications Director and managed U.S. investor relations. She was previously North American Marketing Manager for a division of the company. In prior positions, Christine was Healthcare Group Manager at a Boston public relations firm and led media and government relations efforts for the American Cancer Society in New Hampshire.

Christine holds a Bachelor of Arts degree from the University of Notre Dame and completed a one-year graduate program in business administration at Harvard University. She also holds Series 7 and 63 securities licenses. In her spare time, Christine enjoys exploring the more rural parts of New England on foot, kayak or motorcycle.

Close

Mr. MacDonald has worked with Trout since 2004 and brings over 14 years of experience in healthcare banking, operations and consulting to Trout Capital. David has advised companies at all stages from start-up companies to large, public pharmaceutical companies and has executed transactions in hedge/venture fund placement, private company finance, and business development/M&A.

David began his career as the CFO of Aptagen, Inc, a DNA and protein science company in Northern Virginia. He holds a BA in Economics and Philosophy from Skidmore College and an MPhil and PhD from Cambridge University in Economic Theory. He also holds Series 7 & 63 securities licenses.

Close

 Ms. Glaser joined the firm in 2004, and is based in our San Francisco office where she offers both on-site access to the West Coast investment community as well as support to Trout clients. Prior to joining Trout, she spent a year traveling, and completed research in palliative care and women's health in multi-generational households at the Children's Hospital of Philadelphia. She has provided both U.S. and Australian companies with comprehensive investor relations and strategic development programs.  

Lauren graduated from the University of Pennsylvania with a Bachelor of Arts degree in healthcare management and a minor in nutrition.  She also holds Series 7 and 63 securities licenses.  Lauren enjoys yoga, snowboarding and participates in local triathlons.

Close

Mr. Korb has structured and implemented investor relations programs for a number of companies in the biotech and medical device sectors since joining the firm. He has developed targeted initiatives covering ongoing litigation, financings, partnerships, clinical trials, and earnings and data announcements. Brian has managed investor relations in positive and crisis situations, dealing directly with the institutional, analyst and retail communities. He previously worked as an Assistant Director for the California Public Interest Research Group, a non-profit environmental organization where he headed fundraising efforts in Southern California and attracted media coverage on target issues by drafting press releases and organizing news conferences.

He graduated magna cum laude from Tufts University with a Bachelor of Arts degree in psychology. He is an avid marathon runner and triathlete.  He also holds Series 7 and 63 securities licenses.

Close

At the heart of Mr. Lewis's professional experience is client service; helping clients develop and implement strategies to achieve specific goals and measuring progress along the way. Prior to joining Trout, Seth was a Financial Consultant with Smith Barney where he developed relationships with both individuals and corporations, assisting them with portfolio management and strategic consulting. His background also includes over two years working in estate planning, advising senior citizens on issues regarding Medicare, Medicaid, prescriptions, and long- term care. Seth is based in our Boston office.

Seth has a Bachelor of Arts degree in history from Hartwick College. He also holds Series 7 and 63 securities licenses and is a Series 65 Registered Investment Advisor. Seth is known to have an uncanny knowledge of all things trivial.

Close

Mrs. Nanus is experienced in advising late-stage biotechnology companies in their financing strategies and investor relations programs. She also has global expertise, working with Canadian and Israeli biotechnology companies to create visibility and exposure in the U.S. and European markets.  Prior to joining Trout, Marcy worked in the consumer healthcare division of McCann Erickson.

Marcy received a Bachelor of Business Administration degree in finance, and consulting & venture management from Emory University's Giozueta School of Business. She is the co-founder and program director of the Crohn's and Colitis Foundation of America's Camp Oasis and sits on the foundation's Young Professionals Committee.  She also hold the Series 7 securities license.

Close

Ms. Ogawa brings a diverse scientific background stemming from her four years of research experience in academia and industry. She joined the firm from Medarex, Inc., a monoclonal antibody- focused company, where she helped create a BCL-2 mouse for optimal monoclonal antibody production. She was previously a Research Associate at StemCells, Inc. where she worked in the development of neural markers as they related to monoclonal antibody and protein fragments.

Gitanjali holds a Bachelor of Arts degree in economics from Brown University and a Master of Science degree in biology from New York University. Her research while at New York University focused on the effects of catalase on hematopoietic progenitors. She also holds Series 7 and Series 63 licenses.

Close

Mr. Rubin joined Trout’s after co-heading the Biotechnology Capital Markets Intelligence Group at Thomson Financial, assisting over 60 life sciences companies in their understanding of Wall Street. He brings with him over ten years of experience in advising life science companies on topics including shareholder targeting, capital markets transactions, message crafting and scenario analysis. His experience includes work in finance, consulting and market analysis. He has been involved with companies from pre-IPO stages to follow-on and convertible offerings. He is involved in capital transactions with corporate clients and has counseled clients on domestic and cross-border transactions and binary data events.

Chad holds a Bachelor of Arts degree in business administration with a concentration in finance from Franklin & Marshall College. He has a minor in film and media studies. He also holds Series 7 and 63 securities licenses.

Close

Ms. Yang joined the Trout Group after co-heading the Biotechnology Capital Markets Intelligence Group at Thomson Financial and managed a team of nine analysts and over 50 clients. She brings her investor and capital markets advisory experiences to Trout, giving clients a broader understanding of their market perception, current shareholder base, and targeting practice. Since joining Trout, Christine has assisted on several capital transactions with corporate clients and has counseled clients on cross-border transactions and binary data events. She has been responsible for developing several initiatives at Trout including the Trout Group Client Book and reports such as “Current Market Perceptions in the Life Sciences Investment Community” and “Taking a Look at German Biotech.”

She holds a Bachelor of Arts degree in cultural anthropology from Barnard College, Columbia University. She also holds Series 7 and 63 securities licenses.  Christine enjoys practicing yoga, dancing, and playing tennis in her time away from the office.

Close

 Mr. Rahmer joined the Trout Group in 2007. Peter comes with a diverse academic background complemented by recent work experience as part of Thomson Financial’s Biotechnology Capital Markets Intelligence team. He has experience working with biotech companies ranging from micro-cap to large-cap and pre-clinical to marketed products. Peter has specialized in assisting investor relations efforts encompassing market intelligence, investor targeting, and situation analysis. Peter is based in our San Francisco office.

Peter holds a Bachelor of Arts degree in economics from St. Lawrence University and a Master of Business Administration degree with a concentration in international business from the Rochester Institute of Technology. While obtaining his degrees, Peter had the opportunity to study in China, Scotland and Washington, D.C.  He enjoys traveling and all activities that keep him outdoors.

Close

Close

Ms. Spangler joined Trout in 2009 from Stratton Capital Management. At Stratton, her primary responsibilities included corporate communications and business development for the capital raising process. She holds a FINRA Series 7 and 66 License and is presently a candidate for the Chartered Alternative Investment Analyst (CAIA). 

Prior to joining Stratton, Danielle worked for UBS Wealth Management in Equity Research Sales where she developed client relationships and learned market strategies. Previously, she held a position in Global Operations at Wachovia Bank in Philadelphia.

Danielle received a BS in Economics from the Smeal College of Business at Pennsylvania State University. As part of the Program, she resided in Seville, Spain where she studied the European Union.  

Close

Ms. Fassberg joined Trout as General Counsel from Davis Polk & Wardwell, one of the world’s leading corporate law firms. Ms. Fassberg’s experiences at Davis Polk & Wardwell includes corporate work such as representing investment banks and issuers in various securities offerings, including registered and private placements for domestic and foreign issuers, representing banks in lending transactions, providing advice relating to investment management, as well as general corporate work including corporate governance.

Edith received her Juris Doctorate, magna cum laude, from New York University School of Law in 1997.

Close